Pelage Pharmaceuticals, Inc.
The study is designed to evaluate safety and efficacy of PP405 in adult female participants with androgenetic alopecia
Participants will be randomized 1:1 to PP405 or vehicle and complete a 24 week double blinded treatment period.
Inclusion Criteria: 1. Female (assigned at birth) aged 18 to 65 years, inclusive at time of consent. 2. Able and willing to provide written informed consent 3. Must have been experiencing Androgenetic Alopecia (AGA) for at least 6 months prior to screening. 4. Have a Savin Scale stages I-3, I-4, II-1, or II-2 5. Agree to comply with protocol procedures Exclusion Criteria: 1. Concomitant diagnosis of non-AGA forms of alopecia. 2. Use of other hair loss treatments within periods specified in protocol. 3. Use of excluded medications as specified in protocol. 4. Diagnosis of other medical condi…
Medicated topical gel containing PP405 0.05%
Topical gel